LIT-00814

N/A

Report date: 2025/06/26 16:54:59
NME

Base Information

Drug NameLIT-00814
Drug Alias NameLIT-00814
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase mTOR inhibitorsSerine-protein kinase ATR inhibitors
TargetsSerine/threonine-protein kinase mTORSerine-protein kinase ATR
Therapy Area/IndicationsSolid tumoursEsophageal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Huiqi Biomedical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Huiqi Biomedical Technology Co LtdLittDD Medicines Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursEsophageal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A